Skip to content

4597.T

Solasia Pharma K.K.

グロース · 医薬品 · 医薬品 · JP

JPY 29.00
+0.00%
Ask drillr

Year over year

Reported trailing growth

Revenue
+35.8%
EBITDA
EBIT
+55.9%
EPS
+61.5%
Free cash flow
Operating cash flow
+18.0%

Forward estimates

Based on analyst estimates

Revenue
+203.0%
EBITDA
EPS
+36.2%

Three-year CAGR

Revenue
-26.8%
EBITDA
EBIT
+55.9%
Net income
+54.9%
EPS
+62.2%
Free cash flow
+18.1%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026